Oncovation Pharmaceuticals identifies, develops and partners oncology drugs which will predictably add to the efficacy/synergies of standard and even "standard failed" treatment regimens.

Our strategy involves in-licensing and developing proprietary compounds that are likely chemopotentiators for current chemotherapies in cancer.

We have achieved significant translation success in addressing the problem of so-called "resistant" tumors and of reusing resistant (failed) drugs and partner with research laboratories and biotechnology and pharmaceuticals companies to reinvigorate "failed" or dormant drugs that we can reposition or partner as well as in-license novel compounds.

Collaborations of this sort are mutually beneficial and certainly rewarding. Successfully repositioning a drug will have a significant impact and salvaging a "failed" drug that has been written off can create significant value that will go straight to the bottom line.